The 2020-2021 biotech "bubble" pushed very early-stage companies into public markets prematurely. The subsequent correction, though painful, has been a healthy reset. It has forced the sector back toward a more suitable, long-duration private funding model where companies can mature before facing public market pressures.

While generalist investor interest in biotech is returning, it's not the speculative frenzy of the past. They are avoiding high-risk, early-stage companies and concentrating investments in larger, more understandable, near-commercial businesses like Revolution Medicines, which offer a clearer path to profitability.

Investor sentiment has fundamentally changed. During the COVID era, investors funded good ideas. Now, they want to de-risk their investments as much as possible, often requiring solid Phase 1 and even compelling Phase 2 data before committing significant capital.

Beyond the thesis, first-time biotech funds must explicitly align with LPs on the 6-to-9-year journey from seed to exit. Daniel Fero stresses finding LPs who understand their capital will be locked up for a long duration, unlike in crossover funds with shorter horizons. This "psychological fit" on capital flow expectations is crucial for a stable fund.

In a tight funding environment, a significant portion of startups now secure pharma partnerships *before* their Series A. This pre-validation has become a major draw for VCs, signaling a shift where corporate buy-in is needed to de-risk early-stage science for investors.

The venture capital landscape is bifurcating. Large, multi-stage funds leverage scale and network, while small, boutique funds win with deep domain expertise. Mid-sized generalist funds lack a clear competitive edge and risk getting squeezed out by these two dominant models.

Non-specialist "generalist" investors are re-entering the biotech sector, attracted to a new wave of companies with commercial products and sales data. These are easier to analyze and project than high-risk, preclinical assets. This shift provides crucial capital and signals broader market confidence, as evidenced by their willingness to buy entire follow-on offering deals.

While limited partners in venture funds often claim to seek differentiated strategies, in reality, they prefer minor deviations from established models. They want the comfort of the familiar with a slight "alpha" twist, making it difficult for managers with genuinely unconventional approaches to raise institutional capital.

During the 2022-2025 biotech financing "chill," venture capitalists were so focused on de-risking and protecting their existing portfolios that they wouldn't engage in deep due diligence for preclinical companies like Colonia, regardless of their potential.